Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490529 · ClinicalTrials.gov registry record · Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
A Phase 2 study, sponsored by Ronald Levy.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00490529 is a Phase 2 study that has completed, run by Ronald Levy. The registered enrollment target is 59 participants.
The verdict
NCT00490529, a Phase 2 study, has completed, sponsored by Ronald Levy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.
Interventions
- DRUG Rituximab
- BIOLOGICAL CpG-MCL vaccine
- BIOLOGICAL PF-3512676
- PROCEDURE Vaccine-primed T-cells
- PROCEDURE Autologous hematopoietic stem cell transplant (HSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-08 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490529
The ClinicalTrials.gov registry entry for NCT00490529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ronald Levy, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00490529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490529 about?
NCT00490529 is a clinical study titled "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL". Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time w...
What is the current status of trial NCT00490529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2009-08. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT00490529?
The interventions under investigation include: Rituximab (DRUG), CpG-MCL vaccine (BIOLOGICAL), PF-3512676 (BIOLOGICAL), Vaccine-primed T-cells (PROCEDURE), Autologous hematopoietic stem cell transplant (HSCT) (PROCEDURE).
Who is sponsoring clinical trial NCT00490529?
This trial is sponsored by Ronald Levy, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.